AI Biomed PredictionsCRBP – Corbus Faces Its Next Real Repricing on TEMPO-1 Launch ScanScor Admin / June 9, 2026
AI Biomed PredictionsMNPR – Mid-2026 NDA filing could reignite Monopar’s rare-disease rally ScanScor Admin / June 9, 2026
AI Biomed PredictionsATYR – June IND reset could spark aTyr’s post-failure rebound ScanScor Admin / June 7, 2026
AI Biomed PredictionsZNTL – ASCO follow-through could spark Zentalis’ next ovarian cancer rerating ScanScor Admin / May 31, 2026
AI Biomed PredictionsUNCY – UNCY Faces Make-or-Break FDA Catalyst With Approval Upside ScanScor Admin / May 31, 2026
AI Biomed PredictionsMAIA – Late-Stage NSCLC Progress Could Reawaken MAIA’s Microcap Upside ScanScor Admin / May 31, 2026
AI Biomed PredictionsIMRX – ASCO Data Will Decide Whether IMRX Earns Its Re-Rating ScanScor Admin / May 30, 2026
AI Biomed PredictionsACET – Midyear prula-cel data could redefine ACET’s autoimmune narrative ScanScor Admin / May 30, 2026
AI Biomed PredictionsCRDF – ASCO Data Could Decide Cardiff Oncology’s Next Sharp Repricing ScanScor Admin / May 28, 2026
AI Biomed PredictionsACHV – ACHV Faces Make-or-Break FDA Catalyst With Sharp Upside Potential ScanScor Admin / May 24, 2026
